Table 6. Association with neuropsychiatric symptoms and PD drugs in uni- and multivariate logistic regression analyses.
| Univariate model | Multivariate model* | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of clinical cases/No. of total cases (%) | Unadjusted OR | Adjusted OR | ||||||||||
| Variable | 95%CI | P-value | 95%CI | P-value | ||||||||
| PHQ-9, depression symptoms | ||||||||||||
| L-DOPA, mg | ||||||||||||
| < 600 | 10/30 (33.3) | 1 [reference] | - | 1 [reference] | - | |||||||
| ≥ 600 | 5/8 (62.5) | 3.33 | (0.66 | - | 16.85) | 0.145 | 1.39 | (0.13 | - | 15.26) | 0.787 | |
| Dopamine agonist | ||||||||||||
| without | 6/24 (25.0) | 1 [reference] | - | 1 [reference] | - | |||||||
| with | 9/14 (64.3) | 5.40 | (1.29 | - | 22.6) | 0.021 | 9.33 | (0.85 | - | 102.72) | 0.068 | |
| GAD-7, anxiety symptoms | ||||||||||||
| L-DOPA, mg | ||||||||||||
| < 600 | 15/30 (50.0) | 1 [reference] | - | |||||||||
| ≥ 600 | 4/9 (44.4) | 0.8 | (0.18 | - | 3.57) | 0.77 | ||||||
| Dopamine agonist | ||||||||||||
| without | 9/24 (72.7) | 1 [reference] | - | 1 [reference] | - | |||||||
| with | 10/15 (66.7) | 3.33 | (0.86 | - | 12.92) | 0.082 | 13.07 | (0.81 | - | 210.16) | 0.070 | |
| ISI, insomnia symptoms | ||||||||||||
| L-DOPA, mg | ||||||||||||
| < 600 | 9/30 (30.0) | 1 [reference] | - | |||||||||
| ≥ 600 | 4/9 (44.4) | 1.87 | (0.41 | - | 8.61) | 0.424 | ||||||
| Dopamine agonist | ||||||||||||
| without | 8/24 (33.3) | 1 [reference] | - | |||||||||
| with | 5/15 (33.3) | 1.00 | (0.25 | - | 3.93) | 1.000 | ||||||
Abbreviations: Unadjusted OR, Unadjusted odds ratio; 95%CI, 95% confidence interval; PHQ-9, 9-item Patient Health Questionnaire; GAD-7, 7-item Generalized Anxiety Disorder; ISI, 7-item Insomnia Severity Index.